What benefits are associated with Tesamorelin?

Tesamorelin is studied for: FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta / Egrifta SV), visceral fat reduction via GH/IGF-1 axis — strongest clinical evidence of any fat-targeted peptide, 2 mg/day subcutaneous injection — structured monthly dosing in approved indication, IGF-1 elevation monitoring relevant — considered in metabolic syndrome and diabetes contexts. This reflects the research literature catalogued on PeptideBase — educational only, not medical advice.

Educational use only — not medical advice

Research library

Tesamorelin benefits

From the PeptideBase research library. Educational only — not medical advice.

Studied effects

FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta / Egrifta SV)
visceral fat reduction via GH/IGF-1 axis — strongest clinical evidence of any fat-targeted peptide
2 mg/day subcutaneous injection — structured monthly dosing in approved indication
IGF-1 elevation monitoring relevant — considered in metabolic syndrome and diabetes contexts

Mechanism

Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.